EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB:FCSC.OB) announced that pivotal clinical trial data demonstrating the effectiveness of LAVIV™ (azficel-T) for the improvement of the appearance of moderate-to-severe nasolabial fold wrinkles (“smile lines”) is published online by Dermatologic Surgery, the official, peer-reviewed publication of the American Society for Dermatologic Surgery. It will also be published in an upcoming print issue. LAVIV is a breakthrough aesthetic treatment made from millions of a person’s own living, cultured, collagen-producing fibroblast cells and then injected into smile line wrinkles. This data supported the FDA approval of LAVIV and the publication is another significant development in the company’s stated goal of being the leader in fibroblast evidence-based science.
